We are live on ! Find out more
AIM

AIM ImmunoTech
AIM

15 hedge funds and large institutions have $1.92M invested in AIM ImmunoTech in 2016 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more capital invested

Capital invested by funds: $1.4M → $1.92M (+$521K)

0% more funds holding

Funds holding: 15 → 15 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
15
Holders Change
–
Holders Change %
0%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GC
Guggenheim Capital
Illinois
+$12.8K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$12.8K
3
VKH
Virtu KCG Holdings
New York
+$12.8K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$12.8K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$6.4K
3
Deutsche Bank
Deutsche Bank
Germany
-$6K
4
TSS
Two Sigma Securities
New York
-$3K
5
TRCT
Tower Research Capital (TRC)
New York
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
BIT
1
BlackRock Institutional Trust
California
$766K – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$720K -$6.4K -1 -1%
Renaissance Technologies
3
Renaissance Technologies
New York
$246K – – –
Citadel Advisors
4
Citadel Advisors
Florida
$31K -$12.8K -2 -33%
Northern Trust
5
Northern Trust
Illinois
$27K – – –
OAM
6
Occidental Asset Management
California
$25K – – –
VKH
7
Virtu KCG Holdings
New York
$22K +$12.8K +2 +200%
UBS Group
8
UBS Group
Switzerland
$14K – – –
GC
9
Guggenheim Capital
Illinois
$12K +$12.8K +2 New
Susquehanna International Group
10
Susquehanna International Group
Pennsylvania
$12K +$12.8K +2 New
State Street
11
State Street
Massachusetts
$11K – – –
Bank of New York Mellon
12
Bank of New York Mellon
New York
$9K – – –
BA
13
BlackRock Advisors
Delaware
$9K – – –
BFA
14
BlackRock Fund Advisors
California
$7K – – –
Goldman Sachs
15
Goldman Sachs
New York
$3K – – –
TCM
16
Traynor Capital Management
Pennsylvania
$3K – – –
Millennium Management
17
Millennium Management
New York
$2K – – –
DC
18
Davenport & Co
Virginia
$1.33K – – –
BTS
19
BB&T Securities
Virginia
$1K – – –
CHC
20
City Holding Co
West Virginia
$1K – – –
ICAS
21
Investors Capital Advisory Services
Massachusetts
$1K – – –
Geode Capital Management
22
Geode Capital Management
Massachusetts
$119 – – –
Deutsche Bank
23
Deutsche Bank
Germany
– -$6K -1 Closed
TSS
24
Two Sigma Securities
New York
– -$3K -1 Closed
TRCT
25
Tower Research Capital (TRC)
New York
– -$1K – –

AIM Hedge Fund Activity: Q1 2016 in Review

15 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q1 2016, worth a combined $1.92M — up 37% from $1.4M a quarter earlier.

Fund positioning in AIM was balanced in Q1 2016: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 2 trimmed.

The largest buyer was Guggenheim Capital, opening a new position worth an estimated $12.8K. The largest seller was Citadel Advisors, cutting an estimated $12.8K.

  • 15 institutional investors held AIM ImmunoTech (AIM) as of Q1 2016, unchanged from Q4 2015.
  • Funds reported $1.92M of AIM ImmunoTech stock for Q1 2016, up 37% quarter-over-quarter.
  • 2 funds opened new AIM ImmunoTech positions in Q1 2016 and 2 closed out, a net change of 0 holders.
  • The largest AIM ImmunoTech buyer in Q1 2016 was Guggenheim Capital, an estimated $12.8K added.
  • The largest AIM ImmunoTech seller in Q1 2016 was Citadel Advisors, an estimated $12.8K sold.

Based on aggregated 13F filings for Q1 2016.